Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Kruipen richting de 2 euro
Volgen
NEL schreef op 23 februari 2012 12:19 :
er is genoeg actie vandaag,alleen de verkeerde kant op
Iemand knalt er 10500 bestens uit. Deze aankoop had ik vorige week gezien op 1,75 als ik me goed herinner. Domme particuliere dump dus niets aan de hand!
dus straks maar in 1 keer de laatkant leegkopen
NEL schreef op 23 februari 2012 12:24 :
dus straks maar in 1 keer de laatkant leegkopen
Tja, al vaak zat gedaan echter kunnen sommigen beleggers hun belangen niet vasthouden en dumpen bestens anders stond mdxh stukke hoger!
heeft het voordeel dat er nog goedkoop kan worden ingekocht. reden van het dumpen is dat het voor sommige telang duurt alvorens MDx weer met news komt. zou het weer mooi vinden als we vandaag toch in de 70+ eindigen succes
tjonge tjonge ongelooflijk,met al het goede news dat spoedig gaat komen,zien mensen totaal niet de werkelijke waarde van het bedrijf. marktmaker controleert het boekie en kopers staan langs de zijlijn. 3+ einde van de mnd succes
www.frost.com/prod/servlet/press-rele... nogmaals gelezen en weer overtuigt dat dit spoedig omhoog gaat knallen. succes
finance.yahoo.com/news/amgen-announce... Mdx de volgende kandidaat. Branche is volop in beweging. 3+
Morgen eens kijken of we hem weer in de richting van de 1.80 krijgen.
Mdx zal hem richting de 4 euro brengen Succes
Eerst de bied weer omhoog!
Vandaag kan er een aanval ingezet worden als we de bied boven de 1,77 krijgen. De eerste weerstand ligt dan op 1,85. Voor 30 juni wordt de prostaatkankertest lancering verwacht dus nog 3 maanden voor het grote nieuws! DoC.
De 1,80 is taai maar we naderen hem snel!
Al een paar weken niets meer van Nel vernomen. Waarschijnlijk "met kracht omhoog" gezogen, ergens zwevend in het heelal. De voetjes niet meer helemaal op deze aarde!?
Toch krijgen we weer voldoende kansen om tegen relatief lage prijzen aandelen op te kopen. Al met al wachten we zeer geduldig af op de launch van de prostaatkankertest.
Wat een dump naar 1,62 tussen bied en laat zit nu 10 ct! Iemand nieuws, of iemand die hier zijn belang aan het verkopen is???
social.eyeforpharma.com/opinion/perso... James Clark, vice-president for research and development at MDxHealth, based in Durham, North Carolina, described how DNA methylation patterns can be used as biomarkers for predicting cancer drug activity. One well-described example of this concerns temozolomide, a glioblastoma drug that has achieved blockbuster status. Patients with tumours in which the enzyme O6-methyl guanine methyltransferase (MGMT) has been deactivated by DNA methylation respond much better to this drug, with median overall survival improved by about nine months over similar patients without this methylation. It is now straightforward to detect DNA methylation patterns using second-generation sequencing techniques. MDxHealth is building a workflow to sequence 1,000 complete "reference epigenomes," which will be used to discover markers for cancers and other diseases, and modifying its technology so it can be used to test circulating DNA in readily accessible body fluids.
Mdxhealth is donderdag aanwezig op dit event, zijn zij in staat om die dag de studie resultaten van het biopsy tissue te presenten? We gaan het zien! Ik verwacht dat we weer langzaam omhoog gaan naar nieuwe steunen en weerstanden. Dit event zal nieuwe investeerders werven. Wanneer kunnen we een eind maken aan het kruipen naar de 2 euro? Thursday 19 April 2012 - Register NowBioCapital Europe 2012, organised by LSP (Life Sciences Partners) and ABN AMRO, is delighted to announce its 10th consecutive event, taking place on Thursday 19 April 2012 in Amsterdam, The Netherlands. For the second year running, the event will be held at the luxurious and historic hotel Sofitel Amsterdam The Grand, the former town hall situated in the heart of Amsterdam. BioCapital Europe is Europe's premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to around 40 exciting biotech companies from the Benelux and Europe. Attendance is by invitation only. In 2011, the event attracted 200 attendees (mainly CEOs, CFOs, pharma execs, VCs, and Institutional Investors). VCs and Institutional Investors are invited to attend free of charge to this event. Met vriendelijke groet, DoC.
Dear Shareholders, It is my pleasure to share with you the April 2012 progress report on MDxHealth. In this newsletter, I describe some of our recent accomplishments and the next steps in our strategy for future success. Below are a few of the highlights: In March, we released our fourth quarter and full year 2011 financial results. These figures showed a continued growth in our revenues, particularly in the fourth quarter, where we saw a 48% increase compared to the same period in 2010. This increase is attributable to the uptake of our epigenetic testing platform among the pharma industry. We anticipate future growth in our revenues throughout 2012 predominantly coming from companion diagnostic collaborations and sales of our ConfirmMDx™ for Prostate test after the launch later this year. Operationally, we continue to focus efforts on ensuring our new CLIA laboratory in Irvine is completely up to date. We finished the build out of our R&D facilities. The Irvine facility also received its out of state license from the State of Maryland, which allows the laboratory to receive and process clinical specimens from this state. All US laboratories are required to obtain licenses within their own state, as well as, five others: Maryland, Rhode Island, Pennsylvania, New York and Florida. We have submitted applications for all required out of state licenses and permits. In addition, the company hired four sales managers, one sales director and a director of marketing. These new personnel have many years of experience in the urology/oncology market and are now preparing for the launch of our prostate product in Q2 2012. As MDxHealth establishes its CLIA lab operations and initiates preparations for the launch of its ConfirmMDx for Prostate Cancer test, Miriam Reyes, VP of Lab Operations, provides below some interesting insights about the critical elements to run a CLIA lab. We appreciate your continued interest and support. Sincerely, Jan Groen As we implement our commercial strategy, we continue licensing discussions with the pharmaceutical and biotechnology industry for our epigenetic technology and tests. We are seeing greater acceptance of our approach as demonstrated by the increase in revenues. Recent publications in Nature (Nature 483, 637-639 (28 March 2012) and The Economist (Apr 7th 2012 ) clearly demonstrated that cancer epigenetics is one of the fasted growing fields. Many pharma companies are currently developing epigenetic based drugs. Miriam Reyes, VP of Laboratory Operations at MDxHealth Leading MDxHealth's CLIA laboratory build in preparation for the launch of ConfirmMDx for Prostate Cancer, Miriam Reyes provides below some interesting insights about the critical elements of running a CLIA lab. Beside the physical lab, what other departments are a crucial part of the lab ops? A CLIA lab has several integral departments that ensure the smooth running of operations, including Client Services, Logistics and Accessioning. A brief description of their roles is provided below: Client Services plays a crucial role in representing the company as one of the voices of MDxHealth. Client Services provides the customer service for our external and internal customers. For MDxHealth's existing and prospective customers, the department assists by providing testing information, test order status, logistical support, patient specimen test kit supply replenishment, billing support, as well as, acting as a conduit to the internal operations. The Logistics department coordinates the transportation delivery services and provides customer service reassurance of safe receipt and delivery of patient specimens and test results. The department tracks the patient specimen packages from the time they are picked up from our customer facilities to when they arrive at MDxHealth. The Logistics department also facilitates the timely delivery of patient reports to the customers and safely returns all patient specimen blocks that were used for the assay. The Accessioning department thoroughly reviews each patient case to ensure that the correct information and specimens were received. A reconciliation of patient specimens with the test requisition is performed on each case to confirm the patient test request. Every patient specimen is reviewed thoroughly, entered in the Laboratory Information Management System and barcode labelled for sample processing prior to submission into the laboratory. The accuracy of the information and specimens is crucial as it provides the initial identification of each patient specimen. Client Services plays a crucial role in developing and maintaining client relationships by being proactive and responsive to our client's needs. What is a LIMS system and how is it utilized? LIMS (Laboratory Information Management System) is a data management software program used in diagnostic laboratory settings for tracking and inventory of samples, reagents, and assay test results. In addition to laboratory functionalities, LIMS also includes patient, customer, and billing functionalities allowing for a fully integrated laboratory operations system. The system documents information ranging from account information, assay results, sample inventory, reporting and more in a centralized database, and provides a user interface to facilitate data management across all aspects of laboratory operations. What Quality Assurance Practices are implemented in a clinical laboratory? The laboratory has established, and follows, written policies and procedures as an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the general, pre-analytical, analytical and post-analytical laboratory systems. Such defined quality metrics implemented in MDxHealth's laboratory operations involve the following: Assay Proficiency Testing, Personnel Competency, Qualification of Incoming Reagents, Equipment IQ/OQ/PQ, Bi-annual and Quarterly Equipment Calibrations, Monthly Assay Trending, Barcode labelling, Quarterly Quality Management Reviews and a Corrective Action and Preventative Action Program, all to meet quality value and customer satisfaction. Who is responsible to release the patient results? CLIA laboratories established and licensed in the State of California require a California licensed Clinical Laboratory Scientists (CLSs) to perform and release patient test results. After analysis, the CLS is responsible for the review of the quality control and patient data to determine if the patient test results can be released as an accurate and reliable result to the clinician. The end responsibility lies with the Laboratory Director that is a board certified pathologist with medical credentials and licenses in all of the five required states. How do doctors order the test? ConfirmMDx for Prostate Cancer may be ordered as a test through MDxHealth's test requisition form (TRF). On completing the TRF, clients follow the specimen requirements of the assay; whereby the client prepares, packages and ships the specimen directly to MDxHealth for sample processing. Customers will also have the option to order the assay through an online customer portal in the near future. Dr. Jan Groen, President and CEO of MDxHealth will be presenting at the following conferences: LSP Bio Capital Europe 2012 April 19, 2012 Amsterdam, The Netherlands
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee